hERG Safety Screening for Cardiac Toxicity
Our hERG Safety Screening service employs the Synchropatch-384 automated patch clamp system to assess compound effects on the hERG potassium channel. This high-throughput assay detects inhibitors that may prolong QT intervals and cause arrhythmias, aiding early drug safety evaluation. With precise data under physiological conditions, it supports regulatory compliance to advance safer therapeutics.
hERG Safety Screening for Cardiac Toxicity
Receive your quote directly from the manufacturer.
The hERG channel is essential for cardiac action potential repolarization, and its inhibition by drugs can lead to severe cardiotoxicity. Our service uses the Syncropatch-384 platform for automated, parallel whole-cell voltage clamp experiments, enabling efficient screening of up to 384 channels simultaneously. This provides high-fidelity data, closely mirroring manual patch clamp results, and allows for dynamic compound testing to better prediction of in vivo outcomes.
Key features or benefits:
- Turnaround time: 5 business days
- High-throughput: Provide 10,000+ data points per week via 384-channel system
- Superior precision: pA sensitivity with >95% correlation to manual methods
- Flexible options: Tailored protocols, cell types, and data formats
- Expert analysis: Full support from setup to interpretation
Relevant applications:
- Drug discovery: Early identification of cardiac liabilities
- Preclinical testing: Toxicity profiling for diverse compounds
- Regulatory compliance: CiPA-based proarrhythmia evaluations
- Submission data: Validated results for IND/NDA filings
